Insulet (NASDAQ:PODD) Price Target Increased to $260.00 by Analysts at Jefferies Financial Group

Insulet (NASDAQ:PODD) had its price objective raised by analysts at Jefferies Financial Group from $255.00 to $260.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Jefferies Financial Group’s price target indicates a potential upside of 46.48% from the company’s current price.

Several other research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. increased their price target on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Piper Sandler cut their target price on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. Stifel Nicolaus lifted their price target on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research note on Monday, February 5th. Barclays cut their price objective on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research report on Monday, February 26th. Finally, Wolfe Research raised Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 target price for the company in a report on Tuesday. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $241.67.

Insulet Trading Down 0.0 %

NASDAQ:PODD opened at $177.50 on Friday. Insulet has a 12-month low of $125.82 and a 12-month high of $331.65. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86. The stock’s 50 day simple moving average is $170.59 and its 200-day simple moving average is $181.63. The firm has a market cap of $12.43 billion, a P/E ratio of 61.00, a PEG ratio of 3.14 and a beta of 1.00.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company had revenue of $509.80 million for the quarter, compared to analysts’ expectations of $461.26 million. During the same period in the previous year, the company posted $0.55 EPS. Insulet’s revenue was up 37.9% compared to the same quarter last year. Equities analysts anticipate that Insulet will post 3.08 EPS for the current year.

Insider Activity

In related news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the completion of the transaction, the director now directly owns 2,567 shares in the company, valued at approximately $418,215.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.47% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Capital Research Global Investors raised its position in shares of Insulet by 19.7% in the fourth quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock valued at $2,056,255,000 after buying an additional 1,556,455 shares during the last quarter. Baillie Gifford & Co. acquired a new position in Insulet in the 4th quarter valued at $263,144,000. Norges Bank purchased a new position in shares of Insulet during the 4th quarter worth $227,655,000. William Blair Investment Management LLC boosted its holdings in shares of Insulet by 145.1% during the third quarter. William Blair Investment Management LLC now owns 732,923 shares of the medical instruments supplier’s stock worth $116,894,000 after purchasing an additional 433,884 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of Insulet by 56.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 878,529 shares of the medical instruments supplier’s stock valued at $190,623,000 after purchasing an additional 316,649 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.